Get the Stockscreener App
7.38
0.27%
0.02
After Hours:
7.38
Kezar Life Sciences Inc stock is traded at $7.38, with a volume of 139.93K.
It is up +0.27% in the last 24 hours and up +7.74% over the past month.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
See More
Previous Close:
$7.36
Open:
$7.35
24h Volume:
139.93K
Relative Volume:
2.11
Market Cap:
$54.40M
Revenue:
$7.00M
Net Income/Loss:
$-56.03M
P/E Ratio:
-0.9636
EPS:
-7.6589
Net Cash Flow:
$-51.79M
1W Performance:
+0.00%
1M Performance:
+7.74%
6M Performance:
+71.63%
1Y Performance:
+79.56%
1-Day Range:
$7.34
$7.395
1-Week Range:
$7.32
$7.50
52-Week Range:
$3.5334
$7.55
Kezar Life Sciences Inc Stock (KZR) Company Profile
Name
Kezar Life Sciences Inc
Sector
Industry
Phone
650-822-5600
Address
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
7.38 | 54.25M | 7.00M | -56.03M | -51.79M | -7.6589 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-17-25 | Downgrade | Jefferies | Buy → Hold |
| Oct-17-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-11-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-16-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Wells Fargo | Outperform |
| Jul-16-18 | Initiated | William Blair | Outperform |
View All
Kezar Life Sciences Inc Stock (KZR) Latest News
How activist investor Kevin Tang finally landed the Bay Area company that got away from him - The Business Journals
Are KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders? - Benzinga
M&A Class Action Firm Investigating Multiple Mergers - National Today
Aurinia to Acquire Kezar (NASDAQ: KZR) for $6.955 Cash plus CVR - Stock Titan
Aurinia to buy Kezar (KZR) for $6.955/Share plus CVR (7.39M shares) - Stock Titan
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
Working capital per share of Kezar Life Sciences Inc – FWB:2KZ0 - TradingView — Track All Markets
KZR Technical Analysis & ETF Price Forecast - Intellectia AI
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time - Citeline News & Insights
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - GuruFocus
Weekly Trades: Will Kezar Life Sciences Inc announce a stock splitInsider Buying & Safe Swing Trade Setups - baoquankhu1.vn
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Published on: 2026-04-10 03:01:28 - baoquankhu1.vn
Sectors Review: What are Kezar Life Sciences Incs recent SEC filings showing2026 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Aurinia Pharmaceuticals Acquisition Of Kezar Reshapes Autoimmune Growth And Risks - Sahm
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS - Sahm
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, CNTA, AFBI, and APLS - Morningstar
Growth Value: Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Price Action Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Are KZR, TALK, WBD Obtaining Fair Deals for their Shareholders? - Finviz
Pullback Watch: What is the next catalyst for Kezar Life Sciences Inc2026 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
Shareholder Alert: Ademi LLP investigates whether Kezar - GlobeNewswire
Baselake reports 5.3% stake in Kezar Life Sciences (NASDAQ: KZR) - Stock Titan
Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Volatility Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - msn.com
KZR Technical Analysis & Stock Price Forecast - Intellectia AI
Kezar Life Sciences Announces Lease Termination and Executive Separation Agreements in April 2026 - Minichart
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal - Minichart
KZR PE Ratio & Valuation, Is KZR Overvalued - Intellectia AI
Kezar Life Sciences announces lease termination and executive departures following merger agreement - Investing.com South Africa
Kezar Life Sciences Announces Major Executive Leadership Changes - TipRanks
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline - TipRanks
Aurinia (NASDAQ: AUPH) to acquire Kezar with $6.955 per share cash and CVRs - Stock Titan
Kezar Life Sciences' Christopher J. Kirk, Marc L. Belsky and Mark Schiller to Depart under Separation Agreements - TradingView — Track All Markets
Aurinia to acquire Kezar (NASDAQ: KZR) for $6.955 cash plus CVR - Stock Titan
Kezar Life Sciences, Inc. Announces Resignation of Mark Schiller as Chief Operating Office - marketscreener.com
Major Kezar (KZR) shareholder signs merger support pact and drops bid - Stock Titan
Aurinia Pharmaceuticals: $6.955 Per Share Acquisition Of Kezar Life Sciences To Expand Autoimmune Pipeline - Pulse 2.0
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Zenopa
Trend Recap: What is Kezar Life Sciences Incs market position2026 Chart Watch & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Aurinia to acquire Kezar Life Sciences - The Pharma Letter
Jefferies maintains Kezar Life Sciences stock rating on acquisition By Investing.com - Investing.com India
KZR Acquisition by Aurinia Pharmaceuticals Valued at $6.955 per Share - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Cash Deal - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Strategic Deal - GuruFocus
Jefferies maintains Kezar Life Sciences stock rating on acquisition - Investing.com
After failed takeover bid, activist investor finds new way to buy out Bay Area company - The Business Journals
Aurinia Pharma U.S., Inc. agreed to acquire Kezar Life Sciences, Inc. for $51 million. - marketscreener.com
Shareholder Alert: The Ademi Firm investigates whether Kezar Lif - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR) - PR Newswire
US Market Wrap: Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Macro Moves & Consistent Return Investment Signals - baoquankhu1.vn
Kezar Life Sciences Inc Stock (KZR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):